Mutual of America Capital Management LLC Reduces Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Mutual of America Capital Management LLC lessened its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 7.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 45,313 shares of the medical equipment provider's stock after selling 3,592 shares during the period. Mutual of America Capital Management LLC's holdings in Intuitive Surgical were worth $22,261,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Mirador Capital Partners LP raised its holdings in Intuitive Surgical by 1.4% during the 3rd quarter. Mirador Capital Partners LP now owns 3,526 shares of the medical equipment provider's stock worth $1,732,000 after purchasing an additional 50 shares during the last quarter. Advisors Asset Management Inc. raised its stake in Intuitive Surgical by 18.1% during the first quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider's stock worth $2,945,000 after buying an additional 1,129 shares during the last quarter. Consolidated Planning Corp boosted its position in Intuitive Surgical by 17.4% during the third quarter. Consolidated Planning Corp now owns 8,099 shares of the medical equipment provider's stock valued at $3,979,000 after acquiring an additional 1,198 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in Intuitive Surgical by 617.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 89,069 shares of the medical equipment provider's stock worth $39,622,000 after acquiring an additional 76,649 shares during the period. Finally, Brookstone Capital Management raised its position in shares of Intuitive Surgical by 22.4% in the 2nd quarter. Brookstone Capital Management now owns 12,530 shares of the medical equipment provider's stock worth $5,340,000 after acquiring an additional 2,289 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on ISRG shares. JPMorgan Chase & Co. raised their target price on Intuitive Surgical from $495.00 to $575.00 and gave the stock an "overweight" rating in a research note on Friday, October 11th. Wells Fargo & Company lifted their price objective on shares of Intuitive Surgical from $466.00 to $549.00 and gave the company an "overweight" rating in a research note on Friday, October 18th. Mizuho increased their target price on shares of Intuitive Surgical from $440.00 to $500.00 in a research note on Thursday, October 17th. Raymond James lifted their price target on shares of Intuitive Surgical from $500.00 to $540.00 and gave the company an "outperform" rating in a research note on Monday, October 14th. Finally, Royal Bank of Canada increased their price objective on shares of Intuitive Surgical from $525.00 to $555.00 and gave the stock an "outperform" rating in a research report on Friday, October 18th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $513.74.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG traded down $10.19 during trading on Friday, hitting $527.61. The stock had a trading volume of 1,447,901 shares, compared to its average volume of 1,417,223. The firm has a fifty day moving average of $499.29 and a two-hundred day moving average of $457.89. Intuitive Surgical, Inc. has a 12 month low of $295.02 and a 12 month high of $544.38. The company has a market capitalization of $187.92 billion, a PE ratio of 84.82, a PEG ratio of 5.19 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.24 by $0.32. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. The business had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.01 billion. On average, equities analysts expect that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Jamie Samath sold 269 shares of the firm's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $539.89, for a total transaction of $145,230.41. Following the completion of the sale, the insider now owns 8,757 shares in the company, valued at approximately $4,727,816.73. This trade represents a 2.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Amy L. Ladd sold 450 shares of the business's stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the transaction, the director now owns 821 shares in the company, valued at approximately $402,519.88. The trade was a 35.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 91,178 shares of company stock valued at $45,897,071 over the last three months. Corporate insiders own 0.90% of the company's stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.